Toni M, Anda E, Pineda J, Martínez de Esteban J P, Ollero M D
Servicio de Endocrinología, Hospital de Navarra, Irunlarrea 3, Pamplona, Spain.
An Sist Sanit Navar. 2009 Sep-Dec;32(3):363-70. doi: 10.23938/ASSN.0132.
Amiodarone is a drug widely used for the treatment of arrhythmias. In 16% of amiodarone-treated patients it causes changes in the thyroid function. The aim of this study was to determine the importance of amiodarone-induced thyroid dysfunction in the population of Navarre, studied between 2001 and 2007.
We present a retrospective study that considers the characteristics of 182 amiodarone-treated patients with thyroid dysfunction who had been referred to our Institute. We determined a series of biochemical and instrumental investigations (measurement of thyrotrophin, free thyroid hormones and thyroid autoantibodies; thyroid sonography and thyroid scintigraphy uptake).
Screening of the thyroid function, recommended before starting amiodarone treatment, was carried out in only 20.9 % of the patients. Forty-one percent of patients developed amiodarone induced hypothyroidism; in 76% of them the drug was withdrawn. Hypothyroidism appears after 21 (+/- 12) months of amiodarone treatment. Forty-eight point six developed permanent hypothyroidism. This group of patients had higher serum levels of TSH (thyrotropin) and were treated for less time with amiodarone. Fifty-nine percent of patients developed amiodarone induced thyrotoxicosis; 59.4 % were diagnosed with thyrotoxicosis (AIT) type 1, 30.6% AIT type 2 and the remaining 10 % were diagnosed with mixed thyrotoxicosis. Thyrotoxicosis appears after 29.5 (+/- 17) months of amiodarone treatment. The serum levels of free thyroxine were significantly higher in the AIT type 2 than in the AIT type1. All patients were treated with antithyroid drugs and/or corticoids. Some patients were admitted to hospital due to the severity of their illness.
In our study, amiodarone induced thyrotoxicosis was more frequent than hypothyroidism (59% vs 41%) because Navarre is an iodine-deficient area. It is necessary to control the thyroid function after 2-3 years of amiodarone treatment.
胺碘酮是一种广泛用于治疗心律失常的药物。在接受胺碘酮治疗的患者中,有16%会出现甲状腺功能变化。本研究的目的是确定2001年至2007年间在纳瓦拉人群中胺碘酮所致甲状腺功能障碍的重要性。
我们进行了一项回顾性研究,分析了转诊至我院的182例接受胺碘酮治疗且出现甲状腺功能障碍患者的特征。我们进行了一系列生化和仪器检查(促甲状腺激素、游离甲状腺激素及甲状腺自身抗体测定;甲状腺超声检查和甲状腺闪烁显像摄取)。
仅20.9%的患者在开始胺碘酮治疗前进行了甲状腺功能筛查。41%的患者发生了胺碘酮所致甲状腺功能减退;其中76%的患者停用了该药物。甲状腺功能减退在胺碘酮治疗21(±12)个月后出现。48.6%发生了永久性甲状腺功能减退。这组患者促甲状腺激素(TSH)血清水平较高,且接受胺碘酮治疗的时间较短。59%的患者发生了胺碘酮所致甲状腺毒症;59.4%被诊断为1型甲状腺毒症(AIT),有30.6%为2型AIT,其余10%被诊断为混合型甲状腺毒症。甲状腺毒症在胺碘酮治疗29.5(±17)个月后出现。2型AIT患者的游离甲状腺素血清水平显著高于1型AIT患者。所有患者均接受了抗甲状腺药物和/或皮质类固醇治疗。部分患者因病情严重而入院治疗。
在我们的研究中,由于纳瓦拉是碘缺乏地区,胺碘酮所致甲状腺毒症比甲状腺功能减退更常见(59%对41%)。胺碘酮治疗2至3年后有必要监测甲状腺功能。